Strides Pharma receives USFDA approval for Celecoxib Capsules in multiple strengths
Approval from USFDA allows Strides Pharma to market Celecoxib Capsules 100 mg, 200 mg, and 400 mg in the United States
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Strides Pharma
Strides Pharma recognised in S&P Global Sustainability Yearbook 2025
Strides ranks among the top 10 percent of global companies for ESG performance across environmental, social, and governance…
Strides Pharma subsidiary receives USFDA approval for 60 mg Fluoxetine tablets
Strides Pharma Global secures approval for Fluoxetine Tablets, completing its portfolio for the US market
Strides Pharma secures shareholder and creditor approval for OneSource Pharma CDMO Initiative
Shareholders and creditors back Strides Pharma's plan to create India’s first specialty pharma CDMO
Strides gains USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg
Strides is eligible for 180 days of Competitive Generic Therapy (CGT) exclusivity for Theophylline Extended-Release Tablets, 300…
Strides Alathur receives EIR from USFDA for its Chennai facility
The facility manufactures tablets and capsules and supports several current and future products for the US markets
Glenmark, Strides Pharma and Cipla recall products in US
The recall has taken place due to manufacturing issues
Strides Pharma gets US FDA nod for naproxen sodium softgel capsules
The approval by the US Food and Drug Administration (FDA) is for naproxen sodium softgel capsules of 220 mg strength (over the…
US FDA completes inspection at Stride Pharma’s Singapore facility
The inspection was completed successfully with Zero 483 observations
Strides Pharma recalls six lakh bottles of Losartan Potassium tablets in US
The affected lot of tables, in strengths of 25 mg, 50mg and 100 mg, have been manufactured by Vivimed Life Sciences